TABLE 3.
Sensitivity of TbF6 in combinations with Mtb81 and DPEP with HIV-TB sera (pretreatment) and sera from other disease categories
| Patient statusa | Source | n | Smear | No. (%) positive
|
||
|---|---|---|---|---|---|---|
| TbF6 + DPEP | Mtb81 | TbF6 + DPEP + Mtb81 | ||||
| HIV+-TB+ | Sub-Saharan Africac | 59 | + | 29 | 46 | 49 |
| 5 | − | 1 | 5 | 5 | ||
| Total | 64 | 30 (46.9) | 51 (79.7) | 54 (84.4) | ||
| HIV−-TB+ | Sub-Saharan Africa | 66 | + | 47 (71.2) | 38 (57.6) | 56 (84.8) |
| HIV+-TB− | United States | 11 | 0 | 0 | 0 | |
| PPD+b | Africa-Europe-Asia-Americas | 57 | 3 | 2 | 4 | |
| PPD−b | Africa-Europe-Asia-Americas | 29 | 1 | 0 | 1 | |
| Lung cancer | China | 13 | 0 | 0 | 0 | |
| Bone cancer | China | 4 | 0 | 0 | 0 | |
| Non-TB lung infections | China/Caucasian | 18 | 0 | 1 | 1 | |
| Healthy | China/Caucasian | 9 | 0 | 0 | 0 | |
a
+, positive; −, negative.
b
See Table 2 for geographical distribution.
c
Includes 2 extrapulmonary TB sera and 27 sera previously shown to be negative to the 38-kDa antigen.